leisure time -WSS

leisure time

author：entertainment 2025-09-27 16:49:12 - browse：1369

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： A solution to the after

WSS

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Alabama hospital puts IVF treatments on hold

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

How are insurers handling Leqembi and related scans?

How are insurers handling Leqembi and related scans?

Britney Spears to release memoir, 'The Woman In Me,' later this year

hotspot

leisure time

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

A solution to the after

How one medical school became remarkably diverse

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

United colonoscopy coverage change 'may cost lives,' doctors say

A new nitrogen execution bill also undermines medical licensing

Anesthesiologist group: stop taking Ozempic before surgery

With competition flaring, obesity drug hits goal in liver disease study

Peter Hotez and the public health issue of online harassment

How are insurers handling Leqembi and related scans?

focus

Digital health funding stays low as a new reality sets in

Obesity drugs seen as possible treatment for liver disease MASH

Antibody drugs appear effective. Now can we make enough of them?

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

He's a Nobel laureate. Critics say he was misleading on Covid

Dario to buy mental health app maker Twill in cash and stock deal

leisure time

focus

explore

focus